Extended Erythrocyte Phenotypical Profile in Patients with Sickle Cell Disease: Literature Review and Implications for Transfusion Safety

Abstract

Introduction

Erythrocyte alloimmunization remains a profound and pervasive complication in the clinical management of sickle cell disease (SCD).

Purpose

This study evaluates the global pooled prevalence of red blood cell antibodies and structural minor blood group antigenic variations that compromise transfusion safety across international cohorts.

Methods

Following PRISMA guidelines, a systematic literature search was performed using PubMed and Google Scholar. Nine high-quality observational studies published between 2012 and 2025 were selected, aggregating data from 1,241 multi-transfused SCD patients across four continents. To account for baseline clinical and geographical diversity, raw proportions were normalized via logit transformation and synthesized using a random-effects model.

Results

The global pooled prevalence of erythrocyte alloimmunization among multi-transfused SCD patients was 17.45% (95% CI: [10.09, 26.67]). Extreme statistical heterogeneity was observed (I² = 91.32%, Q = 92.146, p < 0.001), highlighting critical discrepancies between advanced proactive matching facilities (8.05%) and heavily pre-sensitized cohorts (68.42%). Phenotypic risk analysis revealed a 72.72% overall prevalence of the evolutionary null Duffy phenotype Fy(a-b-), a low KEL1 antigen prevalence of 3.32%, and an at-risk Kidd profile rate of 46.57%.

Conclusion

The high 17.45% alloimmunization rate reflects chronic antigenic exposure combined with systematic donor-recipient demographic mismatches. The evolutionary Fy(a-b-)} malaria-resistant profile acts as a major post-transfusion risk barrier when patients receive blood from dominant Caucasian donor pools. Transitioning from basic ABO-RhD compatibility to routine, extended serological phenotyping or molecular genotyping for minor systems (Rh subgroups, Kell, Duffy, Kidd, MNS) is a critical public health priority to eliminate delayed hemolytic transfusion reactions and optimize clinical care. Systematic Review Registration: PROSPERO CRD420261363920.